MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways.

Cancer Cell Int · 2024 · PMC10926683 · PMID 38462628

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

The therapeutic potential of targeting the PD-L1 and miR-34a pathway through immunotherapies may be significant in the treatment of GDLBCL [ 221 ].

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.